Nkarta downgraded to Perform from Outperform at Oppenheimer

Oppenheimer analyst Matthew Biegler downgraded Nkarta Therapeutics to Perform from Outperform without a price target. Amid the progress that bispecific antibodies and commercial CAR-Ts have made to the treatment paradigms of lymphoma and myeloma, NK-cell therapies "are rapidly being left behind," Biegler tells investors in a research note. The analyst says updated data from Nkarta’s NKX019 program, presented earlier in December, "looked encouraging but not encouraging enough to reinvigorate investor interest in the field of NK-cell therapy." He writes, "Simply put, the ship may have already sailed."